A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Viral Hepatitis

Interventions

DRUG: Tobevibart
DRUG: Elebsiran
DRUG: Bulevirtide

Sponsor

Vir Biotechnology, Inc.